A study of 231 cancer patients found that the use of duloxetine (Cymbalta) reduced chemotherapy induce peripheral neuropathy. Patients either recieved Cymbalta or a placebo; in the Cymbalta arm, 59% of patients had an improvement in symptoms, whereas in the placebo arm only 38% of patients had an improvement in symptoms.
The abstract is available here
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
